Video

Dr Sara M. Tolaney: Standard of Care, Novel Approaches for Treatment of HER2-Positive Breast Cancer

There are a lot of new and exciting agents that are being explored for metastatic HER2-positive disease, explained Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute.

There are a lot of new and exciting agents that are being explored for metastatic HER2-positive disease, explained Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute.

Transcript

What’s the current standard of care for HER2-positive breast cancer?

In the metastatic setting, generally, we start out using a taxane with trastuzumab and pertuzumab, and then upon progression, we go on to trastuzumab DM1, and then thereafter, it’s really chemotherapy combined with anti-HER2 therapy. In patients who have hormone-receptor-positive HER2-positive disease, we sometimes will integrate endocrine therapy with dual anti-HER2 therapy along the course of their therapy.

What novel approaches are being taken for the treatment of HER2-positive breast cancer?

There are a lot of new and exciting agents that are being explored for metastatic HER2-positive disease. I think one particular class that’s exciting are the antibody-drug conjugates. So, there’s one agent, the DS-8201a agent. So, it’s an antibody-drug conjugate targeting HER2, and it delivers a topoisomerase 1 payload. They’ve demonstrated about a 60% objective response in metastatic HER2-positive breast cancer, and they uniquely even have activity in HER2-low-positive tumors, with about a 30% response.

Outside of that agent, which is made by Daiichi, there’s several other antibody-drug conjugates. So, here we saw results from a trial looking at SYD985, which is an antibody-drug conjugate that delivers a DNA alkylator payload, and they demonstrated a little over a 30% objective response in pretreated HER2-positive disease. Those 2 agents, along with several other antibody-drug conjugates that are coming along, including now even bispecific antibody-drug conjugates, I think, may really be a great opportunity for a lot of our patients, because you could imagine these agents may either be better than T-DM1 and replace it in the second line setting, or could work in T-DM refractory patients, and so really move into the third line setting.

Related Videos
Picture of San Diego skyline with words ASH Annual Meeting 2024 and health icons overlaid on the bottom
Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program
Screenshot of an interview with Amir Ali, PharmD, BCOP
Mansi Shah, MD, assistant professor, Rutgers Cancer Institute of New Jersey
 Alvaro Alencar, MD, associate professor of clinical medicine, chief medical officer, University of Miami Sylvester Comprehensive Cancer Center
Dr Cesar Davila-Chapa
Sandra Cuellar, PharmD
Screenshot of an interview with Nadine Barrett, PhD
Milind Desai, MD
Masanori Aikawa, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo